Hanmi Pharm. Co., Ltd.

Jin-Sun Kim

Se Chang Kwon

Sung Youb Jung

Sang Hyun Lee

In Young Choi

Myung Hyun Jang

Min Young Kim

Euh Lim Oh

Yong Ho Huh

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment intosp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use ofor animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same

Growing community of inventors

Yongin-si, South Korea

Jin-Sun Kim